yahoo_financeOriginal article
Why argenx (ENXTBR:ARGX) Is Up 11.5% After Positive Autoimmune Myositis Phase 3 Data And What's Next
Phase 3positivePositive
AI Analysis
Summary
argenx announced positive Phase 3 data for an autoimmune myositis candidate, resulting in an 11.5% stock price increase. The company's next steps following this clinical milestone were referenced but not detailed in the provided article excerpt.
Clinical Trial Data
Phase
3
Importance:7/10
Sentiment:
0.80
Phase 3 dataautoimmune myositispositive resultsstock increase
Related Companies
Read the original article
Published by yahoo_finance on August 18, 2026 6:10 AM